Massive arthritis registry aims to unlock secrets of best treatments
NCT ID NCT02530268
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is a large registry that will follow 5,000 people with psoriatic arthritis or spondyloarthritis across North America. Researchers will collect information on how different approved treatments work and their side effects over time. The goal is to better understand these diseases, their natural course, and what treatments are most effective in real-world practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 5,000 people
The number the study aims to enrol. It can still change while the study runs.
- Start date
-
Mar 2013
- Expected to finish
-
Dec 2100
An estimate. End dates often move.
- Lead sponsor
-
A research network
The lead sponsor is a research network or cooperative group.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients are enrolled in the Psoriatic Arthritis and Spondyloarthritis Registry during regularly scheduled office visits. Selected rheumatologists are invited to participate as investigators in the Registry.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
To be eligible for enrollment into the Corrona PsA-SpA Registry, a patient must satisfy all of the inclusion criteria and none of the exclusion criteria listed below. Inclusion Criteria The patient must be: 1. One of the following: 1. Diagnosed with psoriatic arthritis (PsA) and initiating (prescribed or starting) an eligible medication† for the treatment of PsA at the enrollment visit. 2. Meet the ASAS criteria for axial spondyloarthritis (AxSpA), including radiographic or non-radiographic, and initiating (prescribed or starting) an eligible biologic for the treatment of AxSpA at the enrollment visit. 3. Meet the modified New York classification criteria for ankylosing spondylitis (AS) and initiating (prescribed or starting) an eligible biologic for the treatment of AS at the enrollment visit 2. At least 18 years of age or older 3. Able and willing to provide written consent Exclusion Criteria The patient must not be: 1. Diagnosed with rheumatoid arthritis, systemic lupus erythematosus, or any other form of autoimmune inflammatory arthritis. 2. Participating in or planning to participate in a clinical trial with an interventional research study of a non-marketed or marketed investigational drug (e.g. phase I-IV clinical drug trial, post marketing study or registry study where drug is being provided). Of note, concurrent participation in another observational registry study is not excluded. ∆ * Once clinical trial participation has ended, a patient is permitted to enroll in the registry if they satisfy the eligibility requirements at the time of enrollment. If the patient participated in the PsA-SpA registry and was exited to join a clinical trial, the patient cannot be re-enrolled in the PsA-SpA registry after clinical trial participation has ended. Patients switching from an originator biologic to a biosimilar satisfy the enrollment eligibility requirement.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Ankylosing spondylitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can taekwondo kicks ease ankylosing spondylitis?
- Can a Job-Focused rehab program keep arthritis patients employed?
- Can an oral drug calm psoriatic arthritis? phase 3 trial puts deucravacitinib to the test
- Do rheumatic diseases quietly damage the Eye's oil glands?
- Can a questionnaire capture the real burden of psoriatic arthritis?
- Can a new pill calm psoriatic arthritis joint pain?